To identify molecular features associated with the GBM immune microenvironment, we first did differential gene analysis for patients with low immune scores and then combined univariate Cox, lasso regression and RF to identify prognosis-related gene signatures (MEOX2, PHYHIP, RBBP8, ST18, TCF12, and THRB) to establish a risk score approach for GBM patients, followed by multifactorial Cox analysis with clinical information, and risk scores still had significant prognostic power. This evidence concerns the gene THRB and glioblastoma.